1	Risks and long-term prognosis of new-onset heart failure
2	after de novo permanent pacemaker implantation:
3	nationwide cohort study
4	
5	Young Jun Park, MD <sup>a</sup> ; Sungjoo Lee, PhD <sup>b</sup> ; Sungjun Hong, PhD <sup>b,c</sup> ; Kyunga Kim, PhD <sup>b,d*</sup> ;
6	Juwon Kim, MD, PhD <sup>e</sup> ; Ju Youn Kim, MD, PhD <sup>e</sup> ; Kyoung-Min Park, MD, PhD <sup>e</sup> ; Young Keun
7	On, MD, PhD <sup>e</sup> ; Seung-Jung Park, MD, PhD <sup>e*</sup>
8	
9	<sup>a</sup> Division of Cardiology, Department of Internal Medicine, Wonju Severance Christian
10	Hospital, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea
11	<sup>b</sup> Department of Digital Health, Samsung Advanced Institute for Health Sciences &
12	Technology, Sungkyunkwan University, Seoul, Korea
13	<sup>c</sup> Medical AI Research Center, Research Institute for Future Medicine, Samsung Medical
14	Center, Seoul, Republic of Korea
15	<sup>d</sup> Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical
16	Center, Seoul, Korea
17	<sup>e</sup> Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute,
18	Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
19	
20	The first two authors contributed equally to this work.
21	
22	Short title: Prognosis of Pacemaker-associated Heart Failure
23	
24	*Address for correspondence:
25	Seung-Jung Park, MD, PhD
26	Division of Cardiology, Department of Internal Medicine, Heart Vascular and Stroke Institute
27	Samsung Medical Center, Sungkyunkwan University School of Medicine
28	81 Irwon-ro, Gangnam-gu, Seoul, Korea, 06351
29	Tel. +82-2-3410-3419, Fax. +82-2-3410-3849
30	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. E-mail: Orthovics@gmail.com

31

### 32 Kyunga Kim, PhD

- 33 Biomedical Statistics Center, Research Institute for Future Medicine, Samsung Medical Center,
- 34 Department of Digital Health, Samsung Advanced Institute for Health Sciences & Technology,
- 35 Sungkyunkwan University, Seoul, Korea
- 36 Tel. +82-2-3410-6745
- 37 Email: kyunga.j.kim@samsung.com

- 39
- 40 Word count: 4769

### 41 Abstract

42 Background: Previous studies on pacemaker-associated heart failure (PaHF) have 43 predominantly analyzed relatively small, single-center datasets, mainly focusing on incidence 44 and predictors. However, the clinical implications of PaHF on mortality, particularly in relation 45 to standard HF medications or upgrading to cardiac resynchronization therapy (CRT), has been 46 underexplored.

47 Methods: Utilizing nationwide real-world data from the Korean National Health Insurance 48 Service database, we analyzed 32,216 patients undergoing permanent pacemaker (PPM) 49 implantation without preexisting HF between 2008 and 2019. The incidence, predictors, and 50 mortality risk of PaFH were evaluated. To address potential immortal-time bias due to the time-51 dependent occurrence of PaHF, the time from the PPM implantation to the first diagnosis of 52 PaHF was analyzed as a time-dependent covariate. For patients with PaHF, a propensity score-53 matched analysis was conducted based on CRT-upgrade status to explore the effect of CRT-54 upgrade on the risk of all-cause mortality.

55 **Results:** During the median 3.8-year follow-up period, PaHF and all-cause death occurred in 4170 (12.9%) and 6184 (19.2%) of the 32,216 PPM patients (42.3% male, mean age 70.6 years), 56 57 respectively. PaHF development was closely associated with all-cause mortality, with a 58 significantly higher mortality risk in the PaHF than in the non-PaHF group (hazard ratio 59 [HR]=3.11, 95% confidence interval [CI]=2.93–3.32, P<0.001) after adjusting for immortal-60 time bias. The PaHF incidence and PaHF-associated mortality risk, although highest for the 61 first six months post-PPM, did not disappear and increased again with follow-up time. In both 62 the entire cohort (n=4170) and the propensity score-matched cohort (n=1685) of PaHF patients, 63 CRT upgrade (HR=0.34, 95% CI=0.24–0.47, P<0.001), the use of beta-blockers (HR=0.75, 95% CI=0.61-0.93, P=0.010), and angiotensin receptor neprilysin inhibitor (ARNI) use (HR=0.28, 64

65	95% CI=0.14–0.54, P<0.001) were identified as potent protective factors against post-PaHI
66	all-cause mortality.

67	Conclusions: PaHF development independently predicted post-PPM mortality, while
68	upgrading to CRT and the use of beta-blockers or ARNI were identified as favorable prognostic
69	factors for post-PaHF overall survival. Therefore, for PaHF patients, an immediate change into
70	CRT or conduction system pacing, may be required along with optimal HF medications owing
71	to the ongoing mortality risk.

72

73 Keywords: Pacemaker, Heart failure, Mortality, Predictor, Nationwide registry, cardiac

resynchronization therapy, beta-blocker, angiotensin receptor neprilysin inhibitor

75

76

#### 77 Abbreviations

- 78 ACEI: angiotensin-converting-enzyme inhibitors
- 79 AF: atrial fibrillation
- 80 ARB: angiotensin II receptor blockers
- 81 ARNI: angiotensin receptor neprilysin inhibitor
- 82 AVB: atrioventricular block
- 83 CCI: Charlson comorbidity index
- 84 CKD: chronic kidney disease
- 85 CRT: cardiac resynchronization therapy
- 86 DM: diabetes mellitus
- 87 EF: ejection fraction
- 88 ESRD: end-stage renal disease
- 89 MRA: mineralocorticoid receptor antagonists

- 90 PaHF: pacemaker-associated HF
- 91 PPM: Permanent pacemaker
- 92 SND: sinus node dysfunction
- 93
- 94

### 95 Introduction

96 Permanent pacemaker (PPM) implantation is the definitive treatment for patients with
97 symptomatic bradyarrhythmia, such as sinus node dysfunction (SND) or atrioventricular block
98 (AVB). However, pacing-induced left ventricular (LV) electromechanical dyssynchrony can
99 lead to progressive LV dilatation, LV ejection fraction (EF) deterioration, and, eventually,
100 clinical heart failure (HF), which can be specifically defined as pacemaker-associated HF
101 (PaHF). <sup>1-4</sup>

102 PaHF occurs in approximately 6-25% of patients with PPM 2-4 years after implantation.<sup>1,5-7</sup> Several PaHF risk factors have been reported, including older age, male, pre-103 104 existing LV systolic dysfunction, baseline left bundle branch block, right ventricular apical 105 pacing, prolonged paced QRS duration, and a higher right ventricular (RV)-pacing percentage. <sup>1-3,5-8</sup> In addition, patients with PaHF had a significantly higher mortality rate than those without, 106 <sup>1,6</sup> suggesting that a better understanding of PaHF is essential for improving the prognosis of 107 108 this patient population. However, most previous studies on PaHF were single-center studies 109 with relatively small sample sizes, primarily focusing on the incidence and predictors of PaHF. 110 Moreover, the clinical impact of PaHF on mortality has only been evaluated in a limited number of studies.<sup>1,5,6</sup> In addition, the role of standard HF medications or upgrading to cardiac 111 resynchronization therapy (CRT) devices on the prognosis of PaHF has not been thoroughly 112 investigated in a large-scale registry. 113

Accordingly, we sought to investigate the incidence, predictors, and prognosis of PaHF using a nationwide database. Furthermore, we evaluated the effects of standard HF medications or CRT-upgrade on overall mortality in PaHF patients.

#### 117 Methods

#### 118 Data sources

This nationwide retrospective cohort study used data from the National Health Information 119 120 Database (NHID) administered by the Korean National Health Insurance Service. The National 121 Health Insurance Service is a mandatory, single payer social health insurance system that is 122 managed by the Korean government and covers almost the entire ( $\geq$ 52 million) South Korean population.<sup>9</sup> The NHID contains comprehensive information on healthcare services, including 123 124 demographics, diagnoses (based on the International Classification of Disease 10th Revision 125 [ICD-10]), hospital visits and admissions, prescription drugs (based on Anatomical 126 Therapeutic Chemical codes), procedures, medical device usage, and mortality data. It was 127 established nationwide in 2000 and has been accessible to the public on the National Health Insurance Data Sharing Service homepage (http://nhiss.nhis.or.kr), primarily for academic or 128 public policy purposes since 2009.<sup>10,11</sup> Favorable reliability of the diagnostic codes in the 129 130 NHID has previously been reported for major cardiovascular or intractable diseases, such as hypertrophic cardiomyopathy (93% accuracy) or myocardial infarction (92% accuracy).<sup>9,12,13</sup> 131 132 This study was approved by the Institutional Review Board (IRB) of Samsung Medical Center 133 (IRB File No. 2019-05-075). The requirement of informed consent was waived as data are 134 public and deidentified under confidentiality guidelines.

#### 135 Study design and population

Two retrospective cohorts were designed for a twofold purpose. The primary cohort consists of patients with *de novo* PPM implantation without preexisting HF to evaluate the incidence of PaHF and the all-cause mortality risk (PPM Cohort, Supplementary Figure 1). We identified 38,921 adult patients ( $\geq$ 18 years) who underwent *de novo* PPM implantation between January 1, 2008, and December 31, 2019, using the procedure and device codes for claims reimbursement (Supplementary Table 1). We excluded patients who had a previous history of

HF before PPM implantation (n=6,389). The previous history of HF was defined as hospitalization with HF code (I50.9) or prescription history of angiotensin receptor neprilysin inhibitor (ARNI) prior to PPM implantation. Additional exclusions were made for those who underwent reimplantation of a pulse generator and pacing leads following PPM system removal (n=892), or who died on the day of PPM implantation (n=6). Finally, the primary cohort contained 32,216 patients for analyses, including 4,170 patients who developed PaHF and 28,046 patients who did not, respectively.

The secondary cohort consisted only of 4,166 patients who developed PaHF in the primary cohort, excluding 4 who died on the day of PaHF diagnosis (PaHF Cohort, Supplementary Figure 1). The secondary cohort was further stratified into patients who were managed with CRT-upgrade (n=330) and those without (n=3,836) to explore the effect of CRTupgrade on the risk of all-cause mortality. To emulate a randomized controlled trial, we further built a propensity-score (PS) matched cohort of PaHF patients with 1:4 ratio, including 316 and 1,139 patients with and without CRT-upgrade, respectively.

#### 156 Data acquisition

157 Demographic data such as age and sex were obtained. Comorbidities were identified based on 158 ICD-10 codes from claims data between one year before the index date and the date of PaHF 159 (Supplementary Table 2). The Charlson comorbidity index (CCI) that represents the overall 160 comorbidity load at baseline was calculated based on CCI-related variables with their ICD-10 161 codes (Supplementary Table 3). We identified medication history for renin-angiotensin system 162 (RAS) inhibitors including angiotensin-converting-enzyme inhibitors (ACEIs), angiotensin II 163 receptor blockers (ARBs), and ARNI. Information on beta-blockers, mineralocorticoid 164 receptor antagonists (MRAs), loop diuretics, thiazide, antiplatelet agents, and anticoagulants were also retrieved. Pacemaker type and CRT-upgrade were defined using ICD-10 codes for 165 166 cardiac implantable electronic device and procedure (Supplementary Table 1).

#### 167 Study outcomes and follow-up

Two outcomes were considered in the analyses of the primary PPM cohort: the incidences of 168 169 PaHF and all-cause death after *de novo* PPM implantation. First, PaHF was strictly defined as hospitalization with a newly assigned HF code (I50.9) following PPM implantation and  $\geq 2$ 170 171 claims for HF medications among ACEIs/ARBs, beta-blockers, or MRAs. In addition, PPM patients who received CRT-upgrade or ARNI treatment were considered to meet the PaHF 172 173 definition, regardless of HF code assignment or utilization of other HF medications. A broad 174 PaHF definition was further considered to include all patients with a newly assigned HF code. 175 Details of PaHF definitions are summarized in Supplementary Table 4. All main analyses 176 were conducted based on the strict PaHF definition, whereas sensitivity analyses were based 177 on the broad definition. Time-to-PaHF was defined as the time from the date of PPM 178 implantation to the first diagnosis of PaHF during the follow-up. It was censored at the time of 179 death, at the time of new HF-related events developing prior to PaHF diagnosis due to causes 180 other than PaHF, such as myocardial infarction, myocarditis, alcoholic cardiomyopathy, 181 cardiac sarcoidosis, and cardiac amyloidosis (Supplementary Table 5), or at the time of last 182 follow-up (December 31, 2019), whichever came first. Second, post-PPM follow-up duration 183 for all-cause mortality was defined as the time from the date of PPM implantation to the all-184 cause death or the date of last follow-up, whichever came first.

185 The outcome of the secondary PaHF cohort was all-cause death. Post-PaHF follow-up 186 duration for all-cause mortality was defined as the time from the first diagnosis of PaHF to the 187 all-cause death or the date of last follow-up, whichever came first.—

#### 188 Statistical analyses

Baseline characteristics were described as means with standard deviations for continuous variables, and as counts with percentages for categorical variables. Continuous variables were compared using a Student's t-test or Mann–Whitney rank-sum test, whereas categorical

192 variables were compared using the  $\chi^2$  test or Fisher exact test, as appropriate. Incidence rates 193 of PaHF and all-cause death were calculated as events per 100 patient-years (PYs) with exact 194 Poisson 95 % confidence intervals (CIs).

195 The cumulative incidence rate of PaHF was estimated using the Kaplan-Meier (K-M) 196 method. In addition, the instantaneous incidence rate of PaHF was calculated using a 197 nonparametric smoothing method based on B-splines and a generalized linear mixed model 198 across the entire follow-up period. <sup>14</sup> Multivariable Cox proportional hazards (PHs) regression 199 analysis was performed and HRs with 95% CIs were estimated to explore risk factors 200 associated with the occurrence of PaHF.

201 In the analysis of all-cause mortality after de novo PPM implantation, PaHF was 202 considered as a primary exposure. Because PaHF exposure was determined during the follow-203 up period rather than at baseline, there exists a potential immortal-time bias when comparing 204 the mortality risk according to PaHF. Immortal time refers to the duration wherein the outcome could not have occurred until the exposure was determined in observational studies<sup>15</sup>, and was 205 206 the time from the PPM implantation to the first diagnosis of PaHF in this study (Supplementary 207 Figure 2). To account for the potential immortal-time bias, PaHF was considered as a time-208 dependent covariate in the extended K-M estimation and multivariable Cox PH regression 209 analysis. The extended K-M estimator updates the cohorts at each time of PaHF development 210 by allowing the PaHF group to contribute risk to the non-PaHF group before they experience PaHF.<sup>16</sup> In addition, multivariable Cox regression analysis with cubic spline functions was 211 212 performed to investigate the time-varying effect of time-dependent PaHF occurrence on all-213 cause mortality across the entire follow-up period.<sup>17</sup> To evaluate a possible modification on 214 the association between the PaHF and mortality, we conducted subgroup analyses stratified by 215 age (<65, 65-75, and >75 years), sex, comorbidities, pacemaker type (single- vs. dualchamber), pacing indication (AVB vs. SND), and medication (user vs. non-user). The age 216

stratification was determined based on studies and recent guidelines that have developed or recommended risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation (AF). <sup>18-20</sup> The potential modification was tested by assessing the interaction term of each subgrouping variable with PaHF.

221 In the secondary PaHF cohort and also in its PS-matched cohort, post-PaHF all-cause 222 mortality was compared between patient groups treated with and without CRT-upgrade (Supplementary Figure 1). PS was defined as the probability of receiving CRT-upgrade, and 223 224 estimated using a multivariable binary logistic regression model with potential confounders. 225 PaHF patients with CRT-upgrade were matched to those without at a 1:4 ratio by greedy 226 matching without replacement using a caliper width equal to 0.25 times the pooled standard 227 deviation of the logit of the PS. Standardized mean differences (SMDs) were used for balance 228 diagnostics, and absolute values of SMD > 0.1 were considered as significant sign of imbalance. 229 Overall survival curves were estimated by the K-M method, and were compared between the 230 CRT-upgrade and non-upgrade groups using log-rank and stratified log-rank tests in the entire 231 and the PS-matched PaHF cohorts, respectively. Multivariable Cox PH models were used to 232 identify the associations between the CRT-upgrade status and all-cause mortality in both 233 cohorts, and the robust standard errors were estimated by considering matched pairs as clusters 234 in the matched cohort. To account for a potential violation against PH assumption, a sensitivity 235 analysis was conducted using the extended K-M method and multivariable Cox regression with 236 CRT-upgrade considered as a time-dependent covariate.

For our multivariable analysis, we carefully selected variables that have been previously investigated as potential risk factors or confounders for HF or mortality in patients with PPM or cardiovascular diseases. These variables include age, <sup>5,6, 21, 22</sup> sex, <sup>4-7,21-23</sup> diabetes mellitus (DM), <sup>4,5,24</sup> hypertension, <sup>4,6</sup> coronary artery disease, <sup>4,6,21</sup> peripheral artery disease, <sup>25</sup> chronic kidney disease including end stage renal disease (CKD/ESRD), <sup>5,21,26</sup> valvular heart disease, <sup>27</sup>

AF, <sup>8,19,20,27,28</sup> chronic obstructive pulmonary disease, <sup>6,27</sup> pacing indication, <sup>5,22,29-31</sup> CRTupgrade, <sup>2,32</sup> RAS inhibitors, <sup>7,32,33</sup> beta blockers, <sup>7,32,33</sup> MRAs. <sup>7,32,33</sup> To mitigate the risk of overfitting, we included covariates with P values < 0.05 from univariable analyses and clinically relevant variables (such as age and sex) in our multivariable analyses. Additionally, we performed supplementary multivariable analyses, incorporating variables in a nonparsimonious manner within both the primary and secondary cohorts to minimize the risk of inadvertently excluding potentially important variables from the multivariable analysis.

Multicollinearity was assessed by variance inflation factor whose value greater than 4 was considered to indicate non-negligible collinearity. In multivariable time-to-event analyses, the adjusted HRs were reported with 95% CIs. The PH assumption was tested based on the scaled Schoenfeld residuals. Statistical significance was considered with two-sided P values <0.05. Statistical analyses were performed using SAS version 9.3 (SAS Institute, Cary, NC, USA) and R version 4.1.0 (The R Foundation, www.R-project.org).

255

#### 256 **Results**

#### 257 Baseline characteristics of PPM cohort

Among 32,216 PPM patients in the primary cohort, 13,632 (42.3%), 20,246 (63.4%), and 27,073 (84.0%) had male sex, AVB, and dual-chamber PPMs, respectively. The mean age was 70.6±12.1 years. Details of baseline characteristics of PPM cohort are summarized in Table 1. The median follow-up duration was 3.8 (interquartile range, 1.7–6.7) years.

#### 262 **PaHF** incidence and risk factors

New-onset PaHF developed in 4,170 (12.9%) of 32,216 PPM patients with an incidence rate

of 3.3 per 100 PYs (95% CI 3.2–3.4) (Supplementary Figures 1 and 3). The mean time-to-

265 PaHF was 3.0±2.8 years. When the broad PaHF definition was used, PaHF was observed in

 $266 \quad 6,118 (19.0\%)$  patients with much higher incidence rate of 4.9 per 100 PYs (95% CI 4.8–5.0).

267 Patients in the PaHF group exhibited worse baseline features for most variables: more 268 advanced age, a higher proportion of comorbidities, and more frequent use of medications 269 (Table 1). The multivariable Cox regression analysis identified age (as continuous or 270 dichotomous variable), male, and various comorbidities as independent risk factors of PaHF 271 development (Table 2); diabetes mellitus (DM), hypertension, coronary heart disease, chronic 272 kidney disease including end stage renal disease (CKD/ESRD), valvular heart disease, AF, and 273 chronic obstructive pulmonary disease were significantly associated with PaHF occurrence. In 274 contrast, AVB (vs. SND) and peripheral artery diseases did not significantly affect PaHF 275 occurrence after PPM implantation.

#### 276 Risk of all-cause mortality according to the development of PaHF

277 During the study period, all-cause deaths occurred in 6,184 (19.2%) PPM patients. Patients 278 with PaHF had higher incidence rate of all-cause death than those without; 6.2 (95% CI 5.9–6.5) 279 vs. 4.0 (3.9–4.1) per 100 PYs, P <0.001. After adjusting for immortal-time bias, the extended 280 K-M curves also demonstrated worse prognosis of the PaHF compared to non-PaHF groups 281 (Figure 1). On multivariable Cox PH regression analysis, PaHF development was identified as 282 an independent risk factor of post-PPM all-cause mortality (HR 3.11, 95% CI 2.93-3.32, P 283 <0.001), with adjustment for immortal-time bias as well as potential confounders, including 284 age, sex, DM, hypertension, coronary artery disease, peripheral artery disease, CKD/ESRD, 285 valvular heart disease, AF, chronic obstructive pulmonary disease, pacing indication, CCI, 286 types of PPM, and medications (Supplementary Table 6). In most subgroup analyses, patients 287 with PaHF consistently had higher mortality risk than those without (Figure 2).

#### 288 Time courses of PaHF incidence and PaHF-associated mortality

289 The instantaneous incidence rates of strictly- and broadly-defined PaHFs were highest during

- the first 6 months following PPM implantation (Figure 3A). However, they remained above
- 291 zero during the entire follow-up period, making L-shaped curves. Analysis of the time-varying

effect of PaHF on all-cause mortality, revealed that the PaHF-associated mortality risk was
also highest in the first 6 months, then gradually decreased reaching its nadir around 5 years
post-PPM (Figure 3B). Thereafter it began to rise up again with follow-up time, creating a Ushaped curve. Overall, the risk of PaHF-associated mortality remained significantly throughout
the entire follow-up period.

#### 297 Prognosis of patients with PaHF according to CRT-upgrade

Table 3 displayed baseline characteristics at the time of PaHF diagnosis for the entire and PSmatched cohorts of PaHF patients. In the PS-matched cohort, most baseline characteristics were well balanced between the two treatment groups, except for age  $\geq 65$  years (absolute SMD, 0.131) and use of ARNI (0.212) or loop diuretics (0.219).

During the median follow-up period of 1.9 (interquartile range, 0.7-2.6) years, a lower post-PaHF all-cause mortality was observed for the CRT-upgrade group, compared to the nonupgrade group in the entire cohort (incidence rate 4.1 [95% CI 3.0-5.5] vs. 14.6 [13.8-15.3] per 100PYs, P <0.001) and in the PS-matched cohort (4.1 [3.0-5.5] vs. 11.4 [10.3-12.6] per 100PYs, P <0.001). The K-M curve analyses also indicated a better prognosis for PaHF patients with CRT-upgrade compared to those without (log-rank P value <0.001 for the entire cohort and stratified log-rank P value <0.001 for the matched cohort) (Figures 4A and 4B).

309 Patient factors such as age (as a dichotomous or continuous variable), male, DM or 310 CKD/ESRD were significantly associated with increased all-cause mortality, while treatment modalities including CRT-upgrade, RAS inhibitors, and beta-blockers were independent 311 312 protective factors, with the lowest HR observed for CRT-upgrade in multivariable analysis 313 model 1 (HR 0.34, 95% CI 0.24–0.47, P <0.001; Table 4 and Supplementary Table 7). 314 However, when RAS inhibitors were broken down into ACEIs/ARBs and ARNI, only the use of ARNI was identified as a strong protective factor (HR 0.28, 95% CI 0.14-0.54, P < 0.001; 315 316 multivariable analysis model 2 in Table 4 and Supplementary Table 7).

#### 317 Sensitivity analyses

318 Results of sensitivity analyses based on the broad PaHF definition were consistent with the 319 primary results based on the strict definition, demonstrating the PaHF group exhibited a 320 significantly higher mortality than the non-PaHF group in the whole population 321 (Supplementary Figures 4 and 5) and in various subgroup analyses (Supplementary Figure 6). 322 Because the time from PaHF diagnosis to CRT-upgrade was very short (median 0.0, 323 interguartile range 0.0-2.8 months), the immortal-time bias was not expected to be significant. 324 Nonetheless, an additional sensitivity analysis was conducted to adjust for the immortal-time 325 bias introduced by the PaHF-to-upgrade time. The results consistently indicated a significant protective effect of CRT-upgrade on the all-cause death (HR 0.45, 95% CI 0.32-0.63, P 326 327 <0.001), compared to medical treatment alone without CRT-upgrade in patients with PaHF 328 (Supplementary Table 8). In addition, we conducted additional multivariable analyses which 329 incorporated variables in a non-parsimonious manner within both the primary and secondary 330 cohorts. The overall results remained consistent (Supplementary Tables 6 and 9).

331

#### 332 **Discussion**

#### 333 Main findings and merits of this study

Our main findings were: (1) PaHF, when strictly or broadly defined, occurred in 12.9% and 19.0% of PPM patients, respectively, during long-term follow-up of 3.8 (interquartile range, 1.7–6.7) years; (2) the overall post-PPM mortality rate was 19.2%. PaHF development was an independent predictor for post-PPM all-cause death after adjusting for immortal-time bias and other potential confounders, and the risk was approximately three times higher in the PaHF group than in the non-PaHF group; (3) the PaHF incidence and PaHF-associated mortality rates were highest for the first six months post-PPM. However, the risk was likely persistent and

341 increased again with follow-up time (Figures 3A and 3B); and (4) in the entire and propensity-342 matched cohorts of patients with PaHF, CRT-upgrade (HR 0.34), RAS inhibitors (HR 0.71), 343 and beta blockers (HR 0.75) were identified as strong favorable prognostic factors for overall 344 survival. However, when RAS inhibitors were categorized into ACEIs/ARBs and ARNI, a 345 significant association with reduced mortality was observed only in ARNI, not in ACEIs/ARBs. 346 Our study has several merits compared to previous studies. First, this study was based 347 on the two largest real-world cohorts to date: the PPM and PaHF cohorts, potentially enhancing the generalizability of our findings. Second, unlike previous studies<sup>1,6</sup>, we evaluated more 348 349 rigorously the impact of PaHF on mortality risk, by addressing 'the time-dependent occurrence 350 of PaHF' and 'the time-dependent effect of PaHF on mortality'. Third, more importantly, our 351 study is the first to investigate the effects of standard HF medical treatment, particularly the 352 latest RAS inhibitor of ARNI, and upgrading to CRT devices on the prognosis of patients with 353 PaHF, using a propensity score-matched nationwide cohort.

#### 354 **PaHF** incidence and predictors

During the median post-PPM follow-up period of 3.8 (interquartile range, 1.7–6.7) years, the 355 356 PaHF incidence was 12.9% using the strict definition, which likely represented moderate to 357 severe PaHF. However, the incidence increased to 19.0% using the broad definition, probably 358 including mild forms of PaHF as well. Similar to our results, the PaHF incidence was 12.3% 359 in a large single-center study where PaHF was strictly defined by including patients with moderate to severe LV systolic dysfunction.<sup>2</sup> However, a nationwide MarketScan database 360 361 study reported that 25.8% of PPM patients developed PaHF, using a broader PaHF definition 362 based only on the HF diagnosis code.<sup>28</sup>

The independent predictors for PaHF identified in our study were also consistent with previous reports: advanced age ( $\geq 65$  years), male, DM, CKD/ESRD, and AF. <sup>5-7,21,24,28</sup> However, contrary to our initial expectation, AVB was not associated with PaHF risk (Table

366 2). This discrepancy might be because pacing indications (e.g., AVB or SND) cannot reflect 367 exact RV-pacing percentages. For example, in the DANPACE study, patients with SND who 368 were presumed to have a low RV-pacing burden, had a much higher RV-pacing percentage of 85% with dual-chamber PPM implanted.<sup>29</sup> In contrast, in the IDEAL RVP study, the RV-369 pacing burden was below 40% in AVB patients who used PPM algorithms for minimizing RV-370 pacing. <sup>34</sup> This explanation may also be the reason why a large-scale German registry study 371 372 showed no difference in the PaHF incidence (6% vs. 5.3%) or all-cause death (17% vs. 17%) 373 rates between AVB and SND groups.<sup>5</sup>

#### 374 Post-PPM mortality

375 Controversy remains regarding the mortality risk caused by chronic RV-pacing because PPM 376 algorithms for minimizing the RV-pacing burden have failed to reduce all-cause mortality in previous randomized studies and a meta-analysis. <sup>5,22,29-31</sup> However, these unexpected results 377 378 may be related to follow-up periods that were too short (e.g., mean duration of 2.5 years or less) 379 to verify the mortality benefit of the algorithms. Indeed, in our data, the PPM-to-PaHF and 380 PPM-to-death intervals were 3.0±2.8 years and 3.6±2.8 years on average, respectively. 381 Moreover, the risk of post-PPM mortality rise up again approximately 5 years after PPM 382 implant, making a U-shape curve over the entire follow-up period (Figure 3B and 383 Supplementary Figure 5).

In line with previous reports, CKD, male, and advanced age ( $\geq 65$  years) were significantly associated with increased mortality in patients with PaHF (Table 4). In CKD patients, several factors, including ventricular hypertrophy, myocardial fibrosis, and uremia, decelerate myocardial conduction velocity<sup>35,36</sup>, aggravating pacing-induced dyssynchrony. Furthermore, CKD and ESRD have been reported as independent predictors of PaHF and mortality in PPM patients. <sup>6,21,26</sup> Compared to women, men are more likely to have a larger heart size and greater myocardial mass, consequently requiring more time to activate the whole

heart by single-site stimulation, and resulting in a more severe degree of pacing-induced dyssynchrony and higher mortality. <sup>23,37</sup> Greater susceptibility to PaHF in male patients with larger hearts may be a counterpart phenomenon of better CRT responses in female patients with smaller hearts. <sup>38</sup> The specific role of DM on PaHF occurrence or PaHF-associated mortality has rarely been addressed. However, DM is frequently associated with advanced age, CKD/ESRD, and coronary artery disease, which could potentially impact mortality risk. <sup>24,39</sup>

#### 397 **PaHF** prevention

398 When PPM is indicated for patients with preserved EF or no pre-existing HF, prophylactic 399 CRT implantation may not be supported, considering the low incidence of PaHF observed in our data (12.9%) and in the two most recent large-scale registry-based studies (10.6% and 400 25.8%).<sup>21,28</sup> Instead, cardiac conduction system pacing might be the preferred option over 401 402 conventional PPM or prophylactic CRT for patients with multiple risk factors of PaHF, particularly for younger patients with a high predicted RV-pacing burden.<sup>8,40</sup> According to 403 404 our data, the absolute mortality rate was higher in older PPM patients; however, the relative 405 contribution of PaHF to mortality gradually increased in younger age groups (Pinteraction<0.001, 406 Figure 2 and Supplementary Figure 6). In elderly PPM patients, comorbidities would exert a 407 heavier impact on mortality than the RV-pacing burden. In contrast, the prognosis of younger 408 PPM patients might be more strongly affected by the RV-pacing burden because they are likely 409 to have fewer comorbidities but more RV-pacing burden during a longer and more active life.

#### 410 **PaHF monitoring**

After PPM implantation, there are no guidelines regarding when or how often patients with PPM should be monitored for PaHF. Tayal et al. suggested a six-month echocardiographic evaluation would likely identify the majority of PaHF patients based on their findings that the PaHF incidence was significantly higher in the early phase (i.e., within six months post-PPM), whereas the risk significantly decreased during the late phase (i.e., beyond six months).<sup>21</sup>

416 Indeed, our data supported these results, demonstrating that the risk of PaHF or its related 417 mortality was highest within six months (Figures 3A and 3B). However, no recommendation 418 was provided after six months. According to our data, the risk was unlikely to attenuate 419 thereafter. Particularly, PaHF-associated mortality began to rise up again approximately 5 years 420 after PPM implant. Furthermore, risk factors for PaHF or PaHF-associated mortality, such as 421 advanced age (≥65 years), DM, CKD/ESRD, or AF, could be accumulated with time, 422 sustaining or increasing the risks, even after six months post-implantation. Therefore, long-423 term and regular follow-ups of cardiac function may be required after PPM implantation.

#### 424 PaHF management

After a PaHF diagnosis, it is also unclear whether CRT-upgrade should be performed 425 426 immediately or HF medications should be prescribed for a certain period, for example, at least 427 three to six months before CRT-upgrade. In a recent interesting report from Duke University, 428 approximately 60% of patients with left bundle branch block and reduced EF (<35%), exhibited 429 no improvement or even worsening of their LV EF despite three to six months of guideline-430 directed medical therapy (GDMT). Furthermore, the mean LV EF increase was only 2.0%, 431 significantly smaller than that in patients with a narrow QRS (8.0%, P <0.0001). The authors 432 called into question current guidelines that mandate at least three months of GDMT before CRT implantation, particularly in HF patients with left bundle branch block. <sup>33</sup> Likewise, the 433 434 beneficial effect of pre-CRT GDMT was not clear in pacing-dependent HF patients in some studies.<sup>7,32</sup> Indeed, in our study, beneficial effect of MRAs and ACEIs/ARBs were not clear 435 436 in the secondary cohort of patients with PaHF, while only ARNI and beta-blockers were closely 437 associated with reduced mortality (Table 4). Interestingly, our findings appear to corroborate 438 recent guidelines that recommend the prioritized use of ARNI over ACEIs or ARBs in HF patients with reduced EF.<sup>41,42</sup> In addition, the prognosis was significantly better for patients 439 440 who received CRT-upgrade in combination with medical treatment compared to those who

received medical treatment alone without CRT-upgrade. The K-M curve analyses suggest that the prognosis of the two groups began to diverge significantly in the early stages after PaHF diagnosis (Figure 4). Accordingly, immediate changes to biventricular pacing or conduction system pacing along with HF medications, preferably ARNI and beta-blockers, might be a more reasonable option than the delayed upgrade strategy.

The presence of hypertension was also shown to be associated with reduced mortality in the PaHF cohort (Table 5). However, we speculate that this counterintuitive finding is not due to the beneficial effect of hypertension, but rather to the facts that patients with hypertension received HF medications with mortality benefit, especially RAS inhibitors and beta-blockers, much more frequently than those without (absolute SMDs 1.621 and 1.042 for RAS inhibitors and beta-blockers, respectively, Supplementary table 10).

#### 452 *Limitations*

453 We acknowledge several limitations. First, echocardiographic data were not available. 454 Therefore, we could not separately analyze the incidence of PaHF with preserved or reduced 455 EF. However, our sensitivity analysis used the broad PaHF definition, which likely 456 encompassed PaHF patients with preserved EF and demonstrated consistent results with the 457 main outcomes. Second, device interrogation data were lacking for this cohort. Therefore, the 458 correlation between the RV-pacing burden and the risk of PaHF occurrence or associated 459 mortality could not be evaluated quantitatively. In addition, the lack of RV-pacing data raises 460 the question of whether our PaHF cases were caused by RV-pacing-induced electromechanical 461 dyssynchrony. However, in Korea, CRT-upgrades are refundable only when RV-pacing 462 percentage exceeds 40% on PPM interrogation. Moreover, improved survival of PaHF patients 463 after CRT-upgrade is also likely to support that our PaHF patients were really under the detrimental effects of chronic RV-pacing. Next, it may be premature to conclude ARNI is 464 465 superior to ACEIs/ARBs for the management of patients with PaHF. More data are needed to

validate our findings on the efficacy of ARNI in comparison with ACEIs/ARBs. Finally, the
impact of sodium-glucose cotransporter-2 inhibitors on overall mortality was not evaluated due
to the limited number of PaHF patients treated with the agent. Further studies are worth
conducting regarding the efficacy of sodium-glucose cotransporter-2 inhibitors or other novel
HF agents.

However, our study, despite its limitations, may offer valuable insights into the risk profile of
PaHF-associated morality over the entire follow-up period, the optimal timing for CRTupgrade, and the selection of more suitable HF medications for patients with PaHF.

474

#### 475 Conclusions

476 Our nationwide real-world cohort-based study found that PaHF development was closely associated with increased mortality following PPM implantation while upgrading to CRT 477 478 devices and treatment with beta-blockers and ARNI were strong protective factors for all-cause 479 death in patients with PaHF. Furthermore, the PaHF incidence and PaHF-associated mortality 480 were highest during the early post-PPM phase (e.g., within six months), but the risks of PaHF 481 occurrence and associated mortality were likely to continue or increase again with time. 482 Therefore, regular and ongoing cardiac function assessments may be required following PPM 483 implantation. In addition, once PaHF is detected, immediate changes into cardiac physiological 484 pacing modalities, such as biventricular pacemaker or cardiac conduction system pacing, must 485 be considered, along with optimal HF medications.

486

#### 487 Acknowledgement

We thank Mi Yang (Seoul Mental Health Welfare Center) for her great help in retrieving the
raw data, and Professor Minsu Park (Department of Information and Statistics, Chungnam
National University) for his expert opinions on the study design in the early stage of this study.

- 491
- 492 **Funding**
- 493 None declared.
- 494

#### 495 **Disclosure of interest**

- 496 S.J.-P. received research grants from Boston Scientific, Biotronik, Abbott, and Medtronic. K.-
- 497 P. received research grants from Boston Scientific. Y.K.-O. received research grants from
- 498 Bayer AG, Daiichi Sankyo Company. All other authors declare no conflicts of interest.

#### 500 **References**

- Cho SW, Gwag HB, Hwang JK, Chun KJ, Park KM, On YK, Kim JS, Park SJ. Clinical features, predictors, and long-term prognosis of pacing-induced cardiomyopathy. *Eur J Heart Fail*. 2019;21:643-651. doi: 10.1002/ejhf.1427
- 504 2. Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, Kanj M, Wazni OM,
- 505 Saliba WI, Varma N, et al. Incidence and predictors of right ventricular pacing-induced 506 cardiomyopathy in patients with complete atrioventricular block and preserved left 507 ventricular systolic function. *Heart Rhythm*. 2016;13:2272-2278. doi: 508 10.1016/j.hrthm.2016.09.027
- 509 3. Cho EJ, Park SJ, Park KM, On YK, Kim JS. Paced QT interval as a risk factor for new510 onset left ventricular systolic dysfunction and cardiac death after permanent pacemaker
  511 implantation. *Int J Cardiol.* 2016;203:158-163. doi: 10.1016/j.ijcard.2015.10.128
- Boriani G, Vitolo M, Proietti M. Cardiomyopathy associated with long-term right
   ventricular pacing: an intriguing clinical issue. *Eur J Heart Fail*. 2019;21:652-654. doi:
   10.1002/ejhf.1449
- 515 5. Ebert M, Jander N, Minners J, Blum T, Doering M, Bollmann A, Hindricks G, Arentz
  516 T, Kalusche D, Richter S. Long-Term Impact of Right Ventricular Pacing on Left
  517 Ventricular Systolic Function in Pacemaker Recipients With Preserved Ejection
  518 Fraction: Results From a Large Single-Center Registry. *J Am Heart Assoc.* 2016;5. doi:
  519 10.1161/jaha.116.003485
- Dor O, Haim M, Barrett O, Novack V, Konstantino Y. Incidence and Clinical Outcomes
   of Pacing Induced Cardiomyopathy in Patients With Normal Left Ventricular Systolic
   Function and Atrioventricular Block. *Am J Cardiol.* 2020;128:174-180. doi:
   10.1016/j.amjcard.2020.05.017

- 524 7. Khurshid S, Epstein AE, Verdino RJ, Lin D, Goldberg LR, Marchlinski FE, Frankel
- 525 DS. Incidence and predictors of right ventricular pacing-induced cardiomyopathy.
- 526 *Heart Rhythm*. 2014;11:1619-1625. doi: 10.1016/j.hrthm.2014.05.040
- 527 8. Merchant FM, Mittal S. Pacing induced cardiomyopathy. *J Cardiovasc Electrophysiol*.
- 528 2020;31:286-292. doi: 10.1111/jce.14277
- 529 9. Choi EK. Cardiovascular Research Using the Korean National Health Information
  530 Database. *Korean Circ J.* 2020;50:754-772. doi: 10.4070/kcj.2020.0171
- Kim JA, Yoon S, Kim LY, Kim DS. Towards Actualizing the Value Potential of Korea
  Health Insurance Review and Assessment (HIRA) Data as a Resource for Health
  Research: Strengths, Limitations, Applications, and Strategies for Optimal Use of
  HIRA Data. *J Korean Med Sci.* 2017;32:718-728. doi: 10.3346/jkms.2017.32.5.718
- 535 11. Kim JY, Kim SH, Myong JP, Kim YR, Kim TS, Kim JH, Jang SW, Oh YS, Lee MY,
- Rho TH. Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis. J *Am Coll Cardiol.* 2019;73:1123-1131. doi: 10.1016/j.jacc.2018.12.047
- 538 12. Choi YJ, Choi EK, Han KD, Jung JH, Park J, Lee E, Choe W, Lee SR, Cha MJ, Lim 539 WH, et al. Temporal trends of the prevalence and incidence of atrial fibrillation and 540 stroke among Asian patients with hypertrophic cardiomyopathy: A nationwide population-based JCardiol. 2018;273:130-135. 541 study. Int doi: 542 10.1016/j.ijcard.2018.08.038
- 543 13. Park J, Kwon S, Choi E-K, Choi Y-j, Lee E, Choe W, Lee S-R, Cha M-J, Lim W-H,
  544 Oh S. Validation of diagnostic codes of major clinical outcomes in a National Health
  545 Insurance database. *International Journal of Arrhythmia*. 2019;20:1-7.
- 546 14. Rebora P, Salim A, Reilly M. Bshazard: a flexible tool for nonparametric smoothing of
  547 the hazard function. *The R Journal*. 2014;6:114-122.

548 15. Axtell AL, Bhambhani V, Moonsamy P, Healy EW, Picard MH, Sundt TM, 3rd, Wasfy
549 JH. Surgery Does Not Improve Survival in Patients With Isolated Severe
550 Tricuspid Regurgitation. J Am Coll Cardiol. 2019;74:715-725. doi:
551 10.1016/j.jacc.2019.04.028

- Snapinn SM, Jiang Q, Iglewicz B. Illustrating the impact of a time-varying covariate
  with an extended Kaplan-Meier estimator. *The American Statistician*. 2005;59:301-307.
- Heinzl H, Kaider A, Zlabinger G. Assessing interactions of binary time-dependent
   covariates with time in cox proportional hazards regression models using cubic spline
- 556 functions. Stat Med. 1996;15:2589-2601. doi: 10.1002/(sici)1097-
- 557 0258(19961215)15:23<2589::Aid-sim373>3.0.Co;2-o
- Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C,
  Ahlehoff O, Olsen AM, Gislason GH, et al. Validation of risk stratification schemes for
  predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide
  cohort study. *Bmj.* 2011;342:d124. doi: 10.1136/bmj.d124
- Joglar JA, Chung MK, Armbruster AL, Benjamin EJ, Chyou JY, Cronin EM, Deswal
  A, Eckhardt LL, Goldberger ZD, Gopinathannair R, et al. 2023 ACC/AHA/ACCP/HRS
  Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the
- American College of Cardiology/American Heart Association Joint Committee on
  Clinical Practice Guidelines. *Circulation*. 2024;149:e1-e156. doi:
  10.1161/cir.00000000001193
- 568 20. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, Boriani
  569 G, Castella M, Dan GA, Dilaveris PE, et al. 2020 ESC Guidelines for the diagnosis and
  570 management of atrial fibrillation developed in collaboration with the European
  571 Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis
  572 and management of atrial fibrillation of the European Society of Cardiology (ESC)

573	Developed	with th	ne special	contribution	of the	European	Heart	Rhythm	Association

- 574 (EHRA) of the ESC. *Eur Heart J.* 2021;42:373-498. doi: 10.1093/eurheartj/ehaa612
- 575 21. Tayal B, Fruelund P, Sogaard P, Riahi S, Polcwiartek C, Atwater BD, Gislason G,
- 576 Risum N, Torp-Pedersen C, Kober L, et al. Incidence of heart failure after pacemaker
- 577 implantation: a nationwide Danish Registry-based follow-up study. Eur Heart J.
- 578 2019;40:3641-3648. doi: 10.1093/eurheartj/ehz584
- Brunner M, Olschewski M, Geibel A, Bode C, Zehender M. Long-term survival after
  pacemaker implantation. Prognostic importance of gender and baseline patient
  characteristics. *Eur Heart J.* 2004;25:88-95. doi: 10.1016/j.ehj.2003.10.022
- 582 23. Krzemień-Wolska K, Tomasik A, Nowalany-Kozielska E, Jacheć W. Prognosis of
  583 patients with implanted pacemakers in 4-year follow-up : Impact of right ventricular
  584 pacing site. *Herz.* 2018;43:315-324. doi: 10.1007/s00059-017-4561-6
- 585 24. Chen HC, Liu WH, Tseng CH, Chen YL, Lee WC, Fang YN, Chong SZ, Chen MC.
- 586 Diabetes Increases Risk of Cardiovascular Events in Patients Receiving Permanent
  587 Pacemaker: A Propensity Score-Matched Cohort Study. J Diabetes Res.
  588 2022;2022:6758297. doi: 10.1155/2022/6758297
- 589 25. Butt JH, Kondo T, Yang M, Jhund PS, Docherty KF, Vaduganathan M, Claggett BL,
  590 Hernandez AF, Lam CSP, Inzucchi SE, et al. Heart failure, peripheral artery disease,
  591 and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER. *Eur*502 Hernandez AF, 2022;44:2170;2182; dai: 10.1002/undreastil/cheid276
- 592 *Heart J.* 2023;44:2170-2183. doi: 10.1093/eurheartj/ehad276
- 593 26. Liao JN, Chao TF, Tuan TC, Kong CW, Chen SA. Long-term outcome in patients
- 594 receiving permanent pacemaker implantation for atrioventricular block: Comparison of
- 595 VDD and DDD pacing. *Medicine (Baltimore)*. 2016;95:e4668. doi:
- 596 10.1097/md.00000000004668

597 27. Ziaeian B, Fonarow GC. Epidemiology and aetiology of heart failure. *Nat Rev Cardiol*.
598 2016;13:368-378. doi: 10.1038/nrcardio.2016.25

- 599 28. Merchant FM, Hoskins MH, Musat DL, Prillinger JB, Roberts GJ, Nabutovsky Y,
- 600 Mittal S. Incidence and Time Course for Developing Heart Failure With High-Burden
- Right Ventricular Pacing. *Circ Cardiovasc Qual Outcomes*. 2017;10. doi:
  10.1161/circoutcomes.117.003564
- 10.1101/encodecomes.117.00550+
- 603 29. Riahi S, Nielsen JC, Hjortshøj S, Thomsen PE, Højberg S, Møller M, Dalsgaard D, 604 Nielsen T, Asklund M, Friis EV, et al. Heart failure in patients with sick sinus syndrome 605 treated with single lead atrial or dual-chamber pacing: no association with pacing mode 606 or right ventricular pacing site. Europace. 2012;14:1475-1482. doi: 607 10.1093/europace/eus069
- Stockburger M, Boveda S, Moreno J, Da Costa A, Hatala R, Brachmann J, Butter C,
  Garcia Seara J, Rolando M, Defaye P. Long-term clinical effects of ventricular pacing
  reduction with a changeover mode to minimize ventricular pacing in a general
- 611 pacemaker population. *Eur Heart J.* 2015;36:151-157. doi: 10.1093/eurheartj/ehu336
- 612 31. Shurrab M, Healey JS, Haj-Yahia S, Kaoutskaia A, Boriani G, Carrizo A, Botto G,
- 613 Newman D, Padeletti L, Connolly SJ, et al. Reduction in unnecessary ventricular pacing
- fails to affect hard clinical outcomes in patients with preserved left ventricular function:
- a meta-analysis. *Europace*. 2017;19:282-288. doi: 10.1093/europace/euw221
- 616 32. Khurshid S, Obeng-Gyimah E, Supple GE, Schaller R, Lin D, Owens AT, Epstein AE,
- 617 Dixit S, Marchlinski FE, Frankel DS. Reversal of Pacing-Induced Cardiomyopathy
- 618 Following Cardiac Resynchronization Therapy. *JACC Clin Electrophysiol*.
- 619 2018;4:168-177. doi: 10.1016/j.jacep.2017.10.002
- 33. Sze E, Samad Z, Dunning A, Campbell KB, Loring Z, Atwater BD, Chiswell K, Kisslo
  JA, Velazquez EJ, Daubert JP. Impaired Recovery of Left Ventricular Function in

Patients With Cardiomyopathy and Left Bundle Branch Block. J Am Coll Cardiol.
2018;71:306-317. doi: 10.1016/j.jacc.2017.11.020

- Murakami Y, Tsuboi N, Inden Y, Yoshida Y, Murohara T, Ihara Z, Takami M.
  Difference in percentage of ventricular pacing between two algorithms for minimizing
- Difference in percentage of ventricatal pacing setticen the algorithms for minimizing
- 626 ventricular pacing: results of the IDEAL RVP (Identify the Best Algorithm for
- 627 Reducing Unnecessary Right Ventricular Pacing) study. *Europace*. 2010;12:96-102.
- 628 doi: 10.1093/europace/eup252
- 629 35. Boriani G, Savelieva I, Dan GA, Deharo JC, Ferro C, Israel CW, Lane DA, La Manna
- 630 G, Morton J, Mitjans AM, et al. Chronic kidney disease in patients with cardiac rhythm
- 631 disturbances or implantable electrical devices: clinical significance and implications for
- 632 decision making-a position paper of the European Heart Rhythm Association endorsed
- by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. *Europace*.

634 2015;17:1169-1196. doi: 10.1093/europace/euv202

- 635 36. Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular Disease in Chronic
- 636 Kidney Disease: Pathophysiological Insights and Therapeutic Options. *Circulation*.
- 637 2021;143:1157-1172. doi: 10.1161/circulationaha.120.050686
- 638 37. Riesenhuber M, Spannbauer A, Rauscha F, Schmidinger H, Boszotta A, Pezawas T,

639 Schukro C, Gwechenberger M, Stix G, Anvari A, et al. Sex Differences and Long-Term

- 640 Outcome in Patients With Pacemakers. *Front Cardiovasc Med.* 2020;7:569060. doi:
- 641 10.3389/fcvm.2020.569060
- 642 38. Varma N, Lappe J, He J, Niebauer M, Manne M, Tchou P. Sex-Specific Response to
- 643 Cardiac Resynchronization Therapy: Effect of Left Ventricular Size and QRS Duration
- 644 in Left Bundle Branch Block. JACC Clin Electrophysiol. 2017;3:844-853. doi:
- 645 10.1016/j.jacep.2017.02.021

- Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES,
  Korytkowski MT, Munshi MN, Odegard PS, et al. Diabetes in older adults. *Diabetes Care*. 2012;35:2650-2664. doi: 10.2337/dc12-1801
- 649 40. Tokavanich N, Prasitlumkum N, Mongkonsritragoon W, Cheungpasitporn W,
  650 Thongprayoon C, Vallabhajosyula S, Chokesuwattanaskul R. A network meta-analysis
  651 and systematic review of change in QRS duration after left bundle branch pacing, His
  652 bundle pacing, biventricular pacing, or right ventricular pacing in patients requiring
  653 permanent pacemaker. *Sci Rep.* 2021;11:12200. doi: 10.1038/s41598-021-91610-8
- 41. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A,
- Drazner MH, Dunlay SM, Evers LR, et al. 2022 AHA/ACC/HFSA Guideline for the
  Management of Heart Failure: A Report of the American College of
  Cardiology/American Heart Association Joint Committee on Clinical Practice
  Guidelines. *Circulation*. 2022;145:e895-e1032. doi: 10.1161/cir.000000000001063
- 42. Wang Y, Zhou R, Lu C, Chen Q, Xu T, Li D. Effects of the Angiotensin-Receptor
- Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta-Analysis. J Am Heart
  Assoc. 2019;8:e012272. doi: 10.1161/jaha.119.012272
- 662

663

#### 664 Figure legends

665

#### 666 Figure 1. Extended Kaplan–Meier survival curves for all-cause death

- 667 Overall survival of patients with PaHF was significantly reduced compared to those without,
- 668 even adjusted for time from PPM implant to PaHF diagnosis as a time-dependent covariate.
- 669 Hazard ratio (HR) of patients with PaHF relative to those without, along with 95% confidence
- 670 interval (CI) and P value for the difference between the two curves, were derived from the
- 671 corresponding adjusted Cox regression analysis.
- 672 Abbreviations: PaHF, pacemaker-associated heart failure; PPM, permanent pacemaker.
- 673

#### 674 Figure 2. Forest plot of association between PaHF and all-cause mortality by subgroups.

- 675 Patients with PaHF were consistently associated with higher mortality than those without,
- 676 regardless of age, sex, comorbidities, or use of HF medications.

Abbreviations: PaHF, pacemaker-associated heart failure; CI, confidence interval; CAD,
coronary artery disease; PAD, peripheral artery disease; CKD, chronic kidney disease; ESRD,
end-stage renal disease; VHD, valvular heart disease; AF, atrial fibrillation; COPD, chronic
obstructive pulmonary disease; SND, sinus node dysfunction; AVB, atrioventricular block;
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA,
mineralocorticoid receptor antagonist.

683

# Figure 3. Time-varying instantaneous incidence rates of PaHF occurrence (A) and hazard ratio of PaHF on all-cause mortality (B) throughout the entire follow-up period.

Enlarged graphs depicting the first year after PPM implant were overlayed for clarity (A). The
hazard ratios of post-PPM mortality by cubic spline Cox regression analysis were invariably
greater in the PaHF group than in the non-PaHF group throughout the entire follow-up period.

The solid and dashed lines represent the hazard ratio and its 95% confidence interval,respectively (B).

- 691 Abbreviations: PaHF, pacemaker-associated heart failure; PPM, permanent pacemaker.
- 692

### 693 Figure 4. Kaplan–Meier survival curves for all-cause death in the secondary PaHF cohort.

694 The long-term prognosis was significantly improved for patients who received CRT-upgrade

695 in combination with medical treatment compared to those who received medical treatment

- alone without CRT-upgrade.
- 697 Abbreviations: CRT, cardiac resynchronisation therapy; PaHF, pacemaker-associated heart
- 698 failure.
- 699
- 700
- 701 Supplementary Figure Legends

#### 702 Supplementary Figure 1. Study profile

- 703 Abbreviations: PPM, permanent pacemaker; HF, heart failure; PaHF, pacemaker-associated
- heart failure; CRT, cardiac resynchronisation therapy.
- \*, 4 patients died on the day of PaHF diagnosis.
- 706

### 707 Supplementary Figure 2. Graphical depiction of immortal-time bias in the PPM cohort

- 708 Abbreviations: PaHF, pacemaker-associated heart failure; PPM, permanent pacemaker.
- 709

### 710 Supplementary Figure 3. Cumulative incidence rates of PaHF development according to

- 711 strict and broad definitions.
- 712 Abbreviations: PaHF, pacemaker-associated heart failure.
- 713

#### 714 Supplementary Figure 4. Extended Kaplan–Meier survival curves for all-cause death in

#### 715 PPM cohort according to the occurrence of broadly-defined PaHF.

- 716 Abbreviations: PaHF, pacemaker-associated heart failure.
- 717

718	<b>Supplementary</b>	Figure 5.	<b>Time-varying</b>	hazard ratio	of broadl	v-defined	PaHF	on all-
	11 1							

- 719 cause mortality throughout entire follow-up period.
- 720 Hazard ratios across time were estimated using a multivariable Cox regression analysis with a
- 721 cubic spline function. Solid and dashed lines refer to hazard ratio and its 95% confidence
- 722 interval, respectively.
- 723 Abbreviations: PaHF, pacemaker-associated heart failure; PPM, permanent pacemaker.

724

#### 725 Supplementary Figure 6. Forest plot of association between broadly-defined PaHF and 726 all-cause mortality by subgroups.

727 Abbreviations: PaHF, pacemaker-associated heart failure; CI, confidence interval; CAD, 728 coronary artery disease; PAD, peripheral artery disease; CKD, chronic kidney disease; ESRD, 729 end-stage renal disease; VHD, valvular heart disease; AF, atrial fibrillation; COPD, chronic 730 obstructive pulmonary disease; SND, sinus node dysfunction; AVB, atrioventricular block; 731 ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; MRA, 732 mineralocorticoid receptor antagonist.

733

#### Supplementary Figure 7. Graphical depiction of immortal-time bias in the PaHF cohort 734

735 Abbreviations: CRT, cardiac resynchronization therapy; PaHF, pacemaker-associated heart 736 failure.

#### 738 Supplementary Figure 8. Extended Kaplan–Meier survival curves for all-cause death in

#### 739 PaHF cohort.

- 740 Overall survival according to CRT-upgrade after adjusting for immortal-time bias and potential
- 741 confounders (A) before propensity score matching, and (B) after propensity score matching.
- 742 Abbreviations: CRT, cardiac resynchronization therapy; PaHF, pacemaker-associated heart
- 743 failure.

744

### **Table 1.** Baseline characteristics of the PPM cohort

Variables	<b>Overall</b> (n = 32 216)	<b>PaHF</b> (n = 4170)	<b>No PaHF</b> (n = 28 046)	aSMD	P value
Demographics and medical history					
Age, years	$70.6 \pm 12.1$	$71.9 \pm 11.2$	$70.4 \pm 12.2$	0.128	<.001
Age $\geq$ 65 years	24 033 (74.6)	3314 (79.5)	20 719 (73.9)	0.133	<.001
Male	13 632 (42.3)	1815 (43.5)	11 817 (42.1)	0.028	0.093
Diabetes	10 291 (31.9)	1578 (37.8)	8713 (31.1)	0.143	<.001
Hypertension	24 711 (76.7)	3557 (85.3)	21 154 (75.4)	0.250	<.001
Coronary artery disease	13 003 (40.4)	2170 (52.0)	10 833 (38.6)	0.272	<.001
Peripheral artery disease	7453 (23.1)	1015 (24.3)	6438 (23.0)	0.033	0.050
CKD/ESRD	2263 (7.0)	390 (9.4)	1873 (6.7)	0.099	<.001
Valvular heart disease	2976 (9.2)	631 (15.1)	2345 (8.4)	0.211	<.001
Atrial fibrillation	7297 (22.7)	1169 (28.0)	6128 (21.8)	0.143	<.001
COPD	6294 (19.5)	1007 (24.1)	5287 (18.9)	0.129	<.001
$CCI \ge 3$ unit	19 612 (60.9)	2885 (69.2)	16 727 (59.6)	0.200	<.001
Pacemaker-related variables					
AV block	20 246 (63.4)	2502 (60.0)	17 744 (63.3)	0.079	. 001
Sinus node dysfunction	11 675 (36.6)	1631 (39.1)	10 044 (35.8)	0.068	<.001
Dual chamber	27 073 (84.0)	3136 (75.2)	23 937 (85.3)	0.262	<.001
Medications					
ACEIs or ARBs	21 490 (66.7)	3309 (79.4)	18 181 (64.8)	0.328	<.001

Beta blockers	13 905 (43.2)	2390 (57.3)	11 515 (41.1)	0.330	<.001
MRAs	5274 (16.4)	1222 (29.3)	4072 (14.5)	0.363	<.001
Loop diuretics	12 611 (39.1)	2389 (57.3)	10 222 (36.4)	0.427	<.001
Thiazide	6200 (19.2)	1038 (24.9)	5162 (18.4)	0.158	<.001
Antiplatelet agents	19 301 (59.9)	2990 (71.7)	16311 (58.2)	0.287	<.001
Anticoagulants	6382 (19.8)	1127 (27.0)	5255 (18.7)	0.198	<.001

2 Values are expressed as means  $\pm$  standard deviations or n (%).

3 Abbreviations: PPM, permanent pacemaker; PaHF, pacemaker-associated heart failure; aSMD, absolute standardised mean difference; CKD,

4 chronic kidney disease; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; CCI, Charlson comorbidity index; AV

5 block, atrioventricular block; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; MRAs,

6 mineralocorticoid receptor antagonists.

7	Table 2. Independent	risk factors of	pacemaker-ass	ociated heart	failure in the	he PPM cohort
	1		1			

Variable	Univariable analyses		Multivariable analys	is model 1	Multivariable analysis model 2	
variable	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
Age (continuous)	1.03 (1.02 to 1.03)	<.001	1.02 (1.02 to 1.02)	<.001		
Age $\geq$ 65 years	1.77 (1.64 to 1.91)	<.001			1.43 (1.32 to 1.55)	<.001
Male	1.15 (1.08 to 1.22)	<.001	1.09 (1.03 to 1.16)	0.005	1.08 (1.01 to 1.15)	0.023
Diabetes mellitus	1.53 (1.44 to1.63)	<.001	1.15 (1.07 to 1.23)	<.001	1.14 (1.06 to 1.22)	<.001
Hypertension	2.06 (1.90 to 2.25)	<.001	1.41 (1.29 to 1.54)	<.001	1.49 (1.36 to 1.64)	<.001
Coronary artery disease	1.66 (1.56 to 1.77)	<.001	1.35 (1.26 to 1.43)	<.001	1.36 (1.28 to 1.45)	<.001
Peripheral artery disease	1.19 (1.11 to 1.27)	<.001	0.97 (0.90 to 1.04)	0.355	0.97 (0.90 to 1.05)	0.471
CKD/ESRD	2.13 (1.92 to 2.37)	<.001	1.48 (1.32 to 1.65)	<.001	1.49 (1.34 to 1.67)	<.001
Valvular heart disease	1.80 (1.65 to 1.96)	<.001	1.69 (1.55 to 1.84)	<.001	1.65 (1.51 to 1.80)	<.001
Atrial fibrillation	1.92 (1.79 to 2.06)	<.001	1.70 (1.58 to 1.83)	<.001	1.70 (1.58 to 1.84)	<.001
COPD	1.44 (1.34 to 1.54)	<.001	1.18 (1.10 to 1.27)	<.001	1.20 (1.11 to 1.29)	<.001
AVB versus SND	0.90 (0.85 to 0.96)	0.001	0.99 (0.92 to 1.05)	0.679	1.00 (0.94 to 1.07)	0.985

Abbreviations: PPM, permanent pacemaker; HR, hazard ratio; CI, confidence interval; CKD, chronic kidney disease; ESRD, end-stage renal
disease; COPD, chronic obstructive pulmonary disease; AVB, atrioventricular block; SND, sinus node dysfunction.

### **Table 3.** Baseline characteristics of PaHF cohorts

	E	ntire PaHF cohort		PS-matched PaHF cohort			
Variables	<b>CRT-upgrade</b> <sup>*</sup> <b>No CRT-upgrade</b> <sup>*</sup> (n = 330) (n = 3836)		aSMD	<b>CRT-upgrade</b> <sup>*</sup> $(n = 316)$	<b>No CRT-upgrade</b> <sup>*</sup> (n = 1139)	aSMD	
Demographics and medical h	istory						
Age, years	$67.5 \pm 13.7$	$75.6\pm10.5$	0.670	$67.7 \pm 13.4$	$70.3 \pm 12.4$	0.196	
Age $\geq$ 65 years	215 (65.2)	3313 (86.4)	0.511	207 (65.5)	817 (71.7)	0.131	
Male	155 (47.0)	1658 (43.2)	0.075	149 (47.2)	524 (46.0)	0.022	
Diabetes	89 (27.0)	1270 (33.1)	0.134	84 (26.6)	342 (30.0)	0.078	
Hypertension	247 (74.8)	2944 (76.7)	0.044	236 (74.7)	895 (78.6)	0.089	
Coronary artery disease	183 (55.5)	2725 (71.0)	0.328	174 (55.1)	651 (57.2)	0.042	
Peripheral artery disease	113 (34.2)	1573 (41.0)	0.140	111 (35.1)	418 (36.7)	0.033	
CKD/ESRD	39 (11.8)	720 (18.8)	0.194	39 (12.3)	168 (14.7)	0.073	
Valvular heart disease	60 (18.2)	742 (19.3)	0.030	54 (17.1)	176 (15.5)	0.043	
Atrial fibrillation	116 (35.2)	1881 (49.0)	0.284	116 (36.7)	439 (38.5)	0.038	
COPD	117 (35.5)	1793 (46.7)	0.231	111 (35.1)	419 (36.8)	0.035	
Pacemaker-related variables							
AV block	231 (70.0)	2284 (59.5)	0.255	226 (71.5)	790 (69.4)	0.048	
Sinus node disease	90 (27.3)	1524 (39.7)		90 (28.5)	349 (30.6)		
Dual chamber	289 (87.1)	2843 (73.9)	0.338	276 (87.3)	987 (86.7)	0.021	
Medications							

RAS inhibitors <sup>†</sup>	220 (66.7)	2425 (63.2)	0.072	209 (66.1)	786 (69.0)	0.061
ARNI	21 (6.4)	296 (7.7)	0.053	19 (6.0)	126 (11.1)	0.212
Beta blockers	151 (45.8)	1964 (51.2)	0.109	141 (44.6)	523 (45.9)	0.026
MRAs	106 (32.1)	1121 (29.2)	0.063	97 (30.7)	359 (31.5)	0.018
Loop diuretics	146 (44.2)	2151 (56.1)	0.238	135 (42.7)	610 (53.6)	0.219
Thiazide	17 (5.2)	211 (5.5)	0.016	17 (5.4)	52 (4.6)	0.036

12 Values were expressed as means  $\pm$  standard deviations or n (%).

\*, CRT-upgrade and No CRT-upgrade represent patients who were treated with CRT-upgrade plus HF medications and those with HF
 medications alone without CRT-upgrade, respectively.

15 <sup>†</sup>, RAS inhibitors included ACEIs, ARBs, and ARNI.-

Abbreviations: PaHF, pacemaker-associated heart failure; PS, propensity score; CRT, cardiac resynchronisation therapy; aSMD, absolute standardised mean difference; CKD, chronic kidney disease; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; AV block, atrioventricular block; ACEIs, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ARNI, angiotensin receptor neprilysin inhibitor; MRAs, mineralocorticoid receptor antagonists.

Variable	Univariable a	Univariable analyses		ysis model 1	Multivariable anlaysis model 2	
v ar lable	HR (95% CI)	P value	HR (95% CI)	P value	HR (95% CI)	P value
CRT-upgrade	0.36 (0.26 to 0.49)	<.001	0.34 (0.24 to 0.47)	<.001	0.32 (0.23 to 0.45)	<.001
Age $\geq$ 65 years <sup>*</sup>	2.57 (1.98 to 3.33)	<.001	2.53 (1.87 to 3.41)	<.001	2.58 (1.90 to 3.50)	<.001
Male	1.19 (0.99 to 1.44)	0.063	1.26 (1.04 to 1.52)	0.019	1.30 (1.08 to 1.57)	0.006
Diabetes mellitus	1.45 (1.18 to 1.77)	<.001	1.27 (1.02 to 1.58)	0.033	1.25 (1.01 to 1.56)	0.045
Hypertension	0.60 (0.47 to 0.77)	<.001	0.53 (0.39 to 0.71)	<.001	0.46 (0.34 to 0.63)	<.001
Conary artery disease	1.21 (0.99 to 1.48)	0.063				
Peripheral artery disease	1.20 (0.97 to 1.48)	0.098				
CKD/ESRD	2.22 (1.78 to 2.77)	<.001	1.83 (1.44 to 2.32)	<.001	1.77 (1.40 to 2.25)	<.001
Valvular heart disease	0.76 (0.58 to 1.00)	0.048	1.00 (0.75 to 1.33)	0.999	0.97 (0.73 to 1.29)	0.837
Atrial fibrillation	0.72 (0.57 to 0.91)	0.006	0.75 (0.59 to 0.94)	0.014	0.82 (0.65 to 1.04)	0.103
COPD	1.38 (1.13 to 1.69)	0.002	1.22 (1.01 to 1.49)	0.043	1.20 (0.99 to 1.46)	0.063
RAS inhibitors <sup><math>\dagger</math></sup>	0.59 (0.48 to 0.73)	<.001	0.71 (0.56 to 0.88)	0.002		
ACEIs or $ARBs^{\dagger}$	0.71 (0.57 to 0.87)	0.001			0.86 (0.68 to 1.10)	0.239
$ARNI^\dagger$	0.30 (0.16 to 0.55)	<.001			0.28 (0.14 to 0.54)	<.001
Beta blockers	0.66 (0.54 to 0.82)	<.001	0.75 (0.61 to 0.93)	0.010	0.76 (0.61 to 0.93)	0.009
MRAs	1.14 (0.91 to 1.41)	0.248				

## **Table 4.** Independent risk factors of all-cause mortality in the propensity score-matched PaHF cohort

- 22 \*, Age as a continuous variable was also identified as an independent predictor (Supplementary Table 7).
- 23 <sup>†</sup>, RAS inhibitors included ACEIs, ARBs, and ARNI. The variable of RAS inhibitors was included into the Multivariable analysis model 1 as a
- 24 single variable while ACEIs/ARBs and ARNI separately into the Multivariable analysis model 2.
- 25 Abbreviations: PaHF, pacemaker-associated heart failure; PS, propensity score; HR, hazard ratio; CI, confidence interval; CRT, cardiac
- 26 resynchronisation therapy; CKD, chronic kidney disease; ESRD, end-stage renal disease; COPD, chronic obstructive pulmonary disease; ACEIs,
- 27 angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ARNI, angiotensin receptor neprilysin inhibitor; MRAs,
- 28 mineralocorticoid receptor antagonists; AVB, atrioventricular block; SND, sinus node dysfunction; PPM, permanent pacemaker.

# Figure 1



# Figure 2

Subgroups	PaHF (-) events/N, (%)	PaHF (+) events/N, (%)			ŀ	lazard ratios (95% CI)	P value for interaction
Age < 65	456/7327 (6.2)	140/856 (16.4)			-	2.08 (1.72 to 2.51)	<.00001
Age 65-74	1230/8929 (13.8)	429/1366 (31.4)		<b>⊢−</b> −1		1.62 (1.45 to 1.81)	
Age ≥ 75	3050/11790 (25.9)	879/1948 (45.1)	H	•		1.19 (1.11 to 1.29)	
Female	2322/16229 (14.3)	783/2355 (33.2)		H <b>-</b> H		1.77 (1.64 to 1.92)	<.00001
Male	2414/11817 (20.4)	665/1815 (36.6)		⊢■⊣		1.30 (1.19 to 1.41)	
Diabetes -	2769/19333 (14.3)	780/2592 (30.1)		$\mapsto$		1.56 (1.44 to 1.69)	0.0268
Diabetes +	1967/8713 (22.6)	668/1578 (42.3)		H <b>-</b> 1		1.36 (1.25 to 1.49)	
Hypertension -	757/6892 (11.0)	161/613 (26.3)				1.80 (1.52 to 2.14)	0.0107
Hypertension +	3979/21154 (18.8)	1287/3557 (36.2)		H=H		1.41 (1.32 to 1.50)	
CAD -	2561/17213 (14.9)	669/2000 (33.5)		⊢		1.65 (1.52 to 1.80)	0.0012
CAD +	2175/10833 (20.1)	779/2170 (35.9)				1.36 (1.26 to 1.48)	
PAD -	3540/21608 (16.4)	1081/3155 (34.3)		H <b>-</b> H		1.58 (1.47 to 1.69)	0.1329
PAD +	1196/6438 (18.6)	367/1015 (36.2)		⊢		1.40 (1.25 to 1.58)	
CKD/ESRD -	4072/26173 (15.6)	1248/3780 (33.0)		H <b>-</b> H		1.56 (1.47 to 1.67)	<.00001
CKD/ESRD +	664/1873 (35.5)	200/390 (51.3)		4		1.03 (0.88 to 1.21)	
VHD -	4319/25701 (16.8)	1217/3539 (34.4)				1.55 (1.45 to 1.65)	0.3952
VHD +	417/2345 (17.8)	231/631 (36.6)				1.44 (1.23 to 1.70)	
AF -	3848/21918 (17.6)	1150/3001 (38.3)		H		1.59 (1.49 to 1.70)	0.0116
AF +	888/6128 (14.5)	298/1169 (25.5)	ł			1.31 (1.15 to 1.49)	
COPD -	3504/22759 (15.4)	1065/3163 (33.7)		⊢■⊣		1.63 (1.53 to 1.75)	<.00001
COPD +	1232/5287 (23.3)	383/1007 (38.0)	-			1.20 (1.07 to 1.34)	
Charlson score 0-2	1295/11319 (11.4)	358/1285 (27.9)		<b>—</b>		1.79 (1.59 to 2.01)	<.00001
Charlson score $\geq$ 3	3441/16727 (20.6)	1090/2885 (37.8)		H		1.34 (1.25 to 1.43)	
SND	1455/10044 (14.5)	507/1631 (31.1)		<b>⊢−</b> −		1.63 (1.47 to 1.81)	0.2079
AVB	3224/17744 (18.2)	928/2502 (37.1)		H <b>-</b> H		1.51 (1.41 to 1.63)	
Dual chamber	3409/23854 (14.3)	968/3093 (31.3)		H		1.66 (1.55 to 1.79)	<.00001
Single chamber	1308/4109 (31.8)	462/1034 (44.7)				1.04 (0.94 to 1.16)	
ACEi or ARB -	1162/9865 (11.8)	221/861 (25.7)		<b>——</b> —(		1.71 (1.48 to 1.98)	0.0071
ACEi or ARB +	3574/18 <mark>1</mark> 81 (19.7)	1227/3309 (37.1)		H <b>-</b>		1.36 (1.28 to 1.46)	
Beta blocker -	2480/16531 (15.0)	618/1780 (34.7)		$\vdash \bullet \dashv$		1.65 (1.51 to 1.80)	0.0013
Beta blocker +	2256/11515 (19.6)	830/2390 (34.7)				1.37 (1.26 to 1.48)	
MRA -	3704/23974 (15.5)	930/2948 (31.5)				1.51 (1.40 to 1.62)	0.0002
MRA +	1032/4072 (25.3)	518/1222 (42.4)	H	•		1.20 (1.08 to 1.34)	
			1	2	3		
					•		

PaHF (-) worse PaHF (+) worse





Figure 4

(A) Before Propensity Score Matching

# (B) After Propensity Score Matching

